Ratings Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Market Closed - Nasdaq Other stock markets 03:59:52 2024-05-03 pm EDT			5-day change	1st Jan Change
34.52 ^USD	-0.17%		+9.62%	+55.01%

May. 02	Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss	MT
May. 02	Transcript : Agios Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
AGIOS PHARMACEUTICALS, INC.	+55.01%	1.96B	B-
VERTEX PHARMACEUTICALS INCORPORATED	-1.47%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+9.04%	101B	B+
ARGENX SE	+4.40%	23.07B	B
BIONTECH SE	-12.18%	22.23B	B+
GENMAB A/S	-4.36%	18.05B	A-
WUXI APPTEC CO., LTD.	-39.98%	17.18B	A-
BEIGENE, LTD.	-10.23%	16.94B	B
NEUROCRINE BIOSCIENCES, INC.	+6.84%	14.07B	C+
SAREPTA THERAPEUTICS, INC.	+38.66%	12.35B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes